Final Report of the Efficacy and Safety of the Anti-Epidermal Growth Factor Antibody, Cetuximab (IMC-C225), in Combination with Cisplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Refractory to Cisplatin Containing-Ch

Reviewer: Mary Kara Bucci, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 18 de mayo del 2002

Translation for this article does not exist